* If you want to update the article please login/register
Patients in Arm B additionally obtain intravenous DTIC 850mg/m ² on day 1 of each cycle. After informed authorization is offered by the patient a biopsy from a transition should be taken prior to the first intake of research study drug and at the end of cycle 2 to define markers of angiogenesis and MVD.
Source link: https://clinicaltrials.gov/ct2/show/NCT00615160
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions